Want to see SOPH full AI Analyst Report?
SOPH Stock Chart & Stats
$5.72
-$0.33(-5.45%)
At close: 4:00 PM EDT
$5.72
-$0.33(-5.45%)
Day’s Range― - ―
52-Week Range$2.92 - $6.77
Previous CloseN/A
Volume192.98K
Average Volume (3M)100.95K
Market Cap
$475.69M
Enterprise Value$349.16
Total Cash (Recent Filing)$65.39M
Total Debt (Recent Filing)$62.42M
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Aug 04, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.18
Shares Outstanding83,895,260
10 Day Avg. Volume137,858
30 Day Avg. Volume100,949
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)6.69
Price to Sales (P/S)4.08
P/FCF Ratio-8.17
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.00Price Target Upside57.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.81
Revenue Forecast (FY)$93.40M
Bulls Say, Bears Say
Bulls Say
Sustained Revenue And Volume GrowthConsistent top-line growth and rising analysis volumes indicate durable demand for SOPHiA's usage- and subscription-driven model. Higher test throughput supports recurring, volume-linked revenue, improves operating leverage over time, and validates market adoption across clinical and research customers.
Strong Unit Economics / High Gross MarginA sustained high adjusted gross margin (~75%) demonstrates scalable analytics economics: software-centric delivery and data-driven workflows keep incremental costs low. This margin profile supports future operating leverage as volumes grow and helps the company progress toward adjusted-EBITDA improvement.
Strategic Partnerships And Unique Data MoatA JV MOU with MSK and growing biopharma contracts create proprietary data and co-development pathways, strengthening a differentiated analytics offering. This expands clinical validation, accelerates product adoption, and builds a sticky ecosystem advantage that supports long-term commercial and R&D momentum.
Bears Say
Persistent Cash Burn And Operating LossesSubstantial and ongoing negative operating and free cash flow require continued external funding or rapid margin improvement. Persistent cash consumption limits strategic flexibility, increases dilution or leverage risk, and puts execution pressure on management to convert growth into sustainable positive cash generation.
Increased Leverage And Weaker Balance SheetHigher debt relative to equity reduces financial flexibility during a scale-up phase. Elevated leverage raises interest and covenant risks, constrains investments if revenue ramps slow, and magnifies downside if profitability lags the plan, making capital management a critical structural risk.
Ongoing Litigation And FX Cost PressureLegal costs and potential unfavorable rulings create uncertain, recurring expense and potential settlement risk. Significant FX volatility elevates dollar-reported personnel and facility costs in Switzerland, compressing margins and complicating multi-currency budgeting for a business reliant on international scale.
SOPHiA GENETICS News
SOPH FAQ
What was SOPHiA GENETICS’s price range in the past 12 months?
SOPHiA GENETICS lowest stock price was $2.92 and its highest was $6.77 in the past 12 months.
What is SOPHiA GENETICS’s market cap?
SOPHiA GENETICS’s market cap is $475.69M.
When is SOPHiA GENETICS’s upcoming earnings report date?
SOPHiA GENETICS’s upcoming earnings report date is Aug 04, 2026 which is in 2 days.
How were SOPHiA GENETICS’s earnings last quarter?
SOPHiA GENETICS released its earnings results on May 05, 2026. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.232 by -$0.038.
Is SOPHiA GENETICS overvalued?
According to Wall Street analysts SOPHiA GENETICS’s price is currently Undervalued.
Does SOPHiA GENETICS pay dividends?
SOPHiA GENETICS does not currently pay dividends.
What is SOPHiA GENETICS’s EPS estimate?
SOPHiA GENETICS’s EPS estimate is -0.21.
How many shares outstanding does SOPHiA GENETICS have?
SOPHiA GENETICS has 83,895,260 shares outstanding.
What happened to SOPHiA GENETICS’s price movement after its last earnings report?
SOPHiA GENETICS reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.232. Following the earnings report the stock price went down -4.159%.
Which hedge fund is a major shareholder of SOPHiA GENETICS?
Currently, no hedge funds are holding shares in SOPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SOPHiA GENETICS Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.00 (57.34% Upside)
$9.00 (57.34% Upside)
Blogger Sentiment
Bearish
SOPH Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $97.8K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.40%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
7.00%
Trailing 12-Months
Company Description
SOPHiA GENETICS
SOPHiA GENETICS (SOPH) is a healthcare technology company that provides a cloud-based software and data analytics platform used by clinical laboratories and hospitals to analyze complex medical data—primarily genomic sequencing data—to support clinical decision-making in areas such as oncology and inherited/genetic diseases. The company’s core offering is its SOPHiA DDM platform, which standardizes and analyzes raw sequencing outputs and generates results that can be used by clinicians and lab professionals in routine diagnostics and research workflows.
SOPH Company Deck
SOPH Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call portrayed a broadly constructive operational and commercial story: strong top-line growth (22% YoY), record analysis volumes, healthy unit economics (high adjusted gross margin ~75%), improved net dollar retention (117%), and accelerating application and biopharma momentum. Management also took targeted cost actions, expanded liquidity and reaffirmed full-year guidance. Offsetting these positives were higher cash burn, an increased operating loss, FX translation headwinds (Swiss franc up ~14% vs USD), ongoing litigation costs, and softness in Latin America. Growth is expected to be back-half weighted, which introduces execution risk for the year. Overall, the company shows strengthening fundamentals and a clear path toward profitability, but faces near-term cost, FX and legal headwinds that require monitoring.View all SOPH earnings summariesSOPH Stock 12 Month Forecast
Average Price Target
$9.00
▲(57.34% Upside)
Technical Analysis
Schrodinger
―
Zhongchao
―
GeneDx Holdings
―
Definitive Healthcare Corp
―
Omada Health, Inc.
―
Ownership Overview
9.08% Insiders
2.07% Mutual Funds
5.22% Other Institutional Investors
83.53% Public Companies and
Individual Investors